# Teriparatide: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on teriparatide — recombinant human PTH(1-34), the first bone-anabolic osteoporosis drug. Grade A RCT fracture data, a clear anabolic mechanism, and a 2026 status with no controlled-substance restrictions.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Teriparatide is recombinant human PTH(1-34) and the first **bone-anabolic** osteoporosis drug — and it is one of the best-validated peptide drugs in the entire field. Its highest evidence grade is **A**, resting on pivotal and head-to-head fracture-endpoint RCTs. It is an FDA-approved prescription biologic, not a research chemical, and the infamous rat-derived osteosarcoma warning was dropped by the FDA in 2020 after 18 years of human surveillance found no signal.[1](https://peptidevox.com/#r1)[4](https://peptidevox.com/#r4)

Teriparatide (Forteo, PTH 1-34) is the biologically active N-terminal fragment of parathyroid hormone, produced by recombinant DNA technology in *E. coli* and marketed by Eli Lilly. It was FDA-approved in November 2002 as the first bone-building — as opposed to bone-preserving — osteoporosis therapy.[15](https://peptidevox.com/#r15) Unlike most compounds in the peptide-recovery conversation, teriparatide has a deep, completed human randomized-trial base. This monograph separates what is proven from what is extrapolated.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Teriparatide is a prescription drug; decisions about osteoporosis or fracture therapy must be made with a qualified clinician. Dosing figures are reported strictly as seen in the published literature and FDA labeling for completeness — not as recommendations.*

## What is teriparatide and how does it work?

Teriparatide is the first 34 N-terminal amino acids of the 84-residue human parathyroid hormone — the segment that activates the PTH-1 receptor (PTH1R). Its molecular formula is C₁₈₁H₂₉₁N₅₅O₅₁S₂ with a molecular weight of about 4,118 g/mol.[15](https://peptidevox.com/#r15) The defining pharmacologic insight is **dose-timing-dependent biology**: *intermittent* once-daily exposure is net anabolic (bone-forming), whereas *continuous* exposure — as in primary hyperparathyroidism or a continuous infusion — is net catabolic (bone-resorbing).[7](https://peptidevox.com/#r7)

The once-daily subcutaneous injection produces a sharp, transient PTH1R activation that preferentially drives the cAMP/PKA/CREB cascade favoring osteoblast differentiation and survival, before returning to baseline too quickly to sustain the RANKL upregulation that would drive osteoclastogenesis.[8](https://peptidevox.com/#r8) Mechanistically, teriparatide increases osteoblast number and activity chiefly through an anti-apoptotic effect (prolonged osteoblast survival) and by reactivating quiescent bone-lining cells; it activates canonical Wnt/β-catenin signaling, partly by suppressing osteocyte secretion of the bone-formation inhibitor sclerostin, and raises local IGF-1.[8](https://peptidevox.com/#r8) Because formation and resorption are coupled, each remodeling unit ends in a positive bone balance, with an early 'anabolic window' of formation outpacing resorption; the bone-formation marker P1NP rises within 1–3 months and is used clinically to confirm response.[9](https://peptidevox.com/#r9) Subcutaneous bioavailability is about 95%, peak serum concentration occurs roughly 30 minutes after injection, and serum half-life is about one hour — the brief exposure *is* the mechanism.[15](https://peptidevox.com/#r15)

## What is the evidence by indication?

Teriparatide's evidence is anchored by two large fracture-endpoint randomized trials. In the pivotal Fracture Prevention Trial, 1,637 postmenopausal women with prior vertebral fractures were randomized to placebo or teriparatide (20 µg or 40 µg daily) for a median of about 19–21 months; new vertebral fractures fell from 14% on placebo to 5% on 20 µg (RR 0.35), and nonvertebral fragility fractures fell from 6% to 3%.[1](https://peptidevox.com/#r1) The full registry record for the broader teriparatide program can be reviewed at [ClinicalTrials.gov](https://clinicaltrials.gov/). The active-comparator VERO trial then randomized 1,360 women with severe osteoporosis to teriparatide versus oral risedronate over 24 months: new vertebral fractures were 5.4% versus 12.0% (RR 0.44, p
  Teriparatide evidence by indication

    IndicationBest evidenceGrade

    Postmenopausal osteoporosis — fracture reductionPivotal Fracture Prevention Trial (n=1,637) + VERO head-to-head (n=1,360)A
    Glucocorticoid-induced osteoporosisFDA-approved; superior to alendronate on spine BMD & vertebral fractureA
    Male (primary/hypogonadal) osteoporosisBMD-endpoint RCTs; smaller fracture base than the female programA/B
    Off-label fracture healing — time to unionMeta-analysis of 5 RCTs (n=380); hip-fracture meta-analysisB
    Off-label fracture healing — hard union ratesNo improvement in union rates, reoperation or mortality (hip)C

Teriparatide is also FDA-approved for glucocorticoid-induced osteoporosis, where head-to-head data show it superior to alendronate on spine BMD and vertebral-fracture reduction, and for increasing bone mass in men with primary or hypogonadal osteoporosis on BMD-endpoint trials.[15](https://peptidevox.com/#r15)[16](https://peptidevox.com/#r16) The most-extrapolated indication — and the one most relevant to bone-healing content — is off-label fracture healing, and it must be framed honestly. A meta-analysis of 5 RCTs (n=380) found teriparatide can shorten time to union at the 20 µg dose, and a hip-fracture meta-analysis (n=607) found it reduced time to union by about two weeks (WMD −1.95 weeks, p=0.003) — but that same analysis found **no** improvement in union rates at 3 or 6 months and no reduction in reoperation or mortality.[10](https://peptidevox.com/#r10)[11](https://peptidevox.com/#r11) A 2023 systematic review of 32 mostly-case-series reports concluded teriparatide is safe and useful for inducing callus, but the high-quality base is thin.[12](https://peptidevox.com/#r12)[13](https://peptidevox.com/#r13)

Proven vs hyped
Proven: fracture *prevention* in osteoporosis (Grade A), superior to a standard antiresorptive. Hyped: teriparatide as a general 'bone-healing peptide.' For off-label fracture healing it likely shortens time-to-union and aids callus (Grade B) but has not been shown to raise hard union rates (Grade C). It is not FDA-approved for fracture acceleration.[10](https://peptidevox.com/#r10)[11](https://peptidevox.com/#r11)

## What doses appear in the literature?

Reported strictly as information, not a protocol. The marketed and clinical dose is 20 µg subcutaneously once daily, delivered by a prefilled multi-dose pen and injected into the thigh or abdominal wall; first doses are given where the patient can sit or lie down because of early orthostatic risk.[4](https://peptidevox.com/#r4) The Fracture Prevention Trial tested 20 µg and 40 µg, but 40 µg gave more BMD with more adverse effects and no added fracture benefit, so 20 µg is standard.[1](https://peptidevox.com/#r1) Duration was historically capped at 24 months lifetime; the FDA removed that limit in November 2020, so duration is now individualized to fracture risk and BMD response.[6](https://peptidevox.com/#r6) Because BMD gains are lost after stopping, an antiresorptive (bisphosphonate or denosumab) is typically given afterward in a widely used 'anabolic-first, then antiresorptive' sequence; trials co-administered calcium and vitamin D.[9](https://peptidevox.com/#r9) The product is a refrigerated pen, supplied as 600 µg/2.4 mL for 28 days of clinical use.[19](https://peptidevox.com/#r19)

## How safe is teriparatide?

The common adverse events from RCTs are well characterized: transient hypercalcemia (about 11% of patients in the pivotal trial, largely self-resolving), nausea, headache, dizziness, leg cramps, orthostatic hypotension after the first few doses, injection-site reactions, and mild hyperuricemia.[1](https://peptidevox.com/#r1)[7](https://peptidevox.com/#r7) The central historical concern was osteosarcoma: lifetime, high-dose rat studies showed dose- and duration-dependent osteosarcoma, prompting the original boxed warning and 2-year cap. Across 18 years of human post-marketing surveillance — including large claims-linked cohort studies cross-referenced with cancer registries — **no increased osteosarcoma incidence** was observed, so the FDA removed the boxed warning and the 2-year limit on November 16, 2020, a model of evidence-driven de-risking.[4](https://peptidevox.com/#r4)[5](https://peptidevox.com/#r5)

Because of that historical signal, teriparatide is contraindicated or used with caution in populations with elevated baseline bone-tumor risk or bone turnover: Paget's disease of bone; open epiphyses (children and young adults with a growing skeleton); prior skeletal radiation; bone metastases or skeletal malignancy; hereditary metabolic bone disorders; and pre-existing hypercalcemia or primary hyperparathyroidism. Caution also applies in active urolithiasis given the calcium effects, and with digoxin (hypercalcemia can predispose to digitalis toxicity).[15](https://peptidevox.com/#r15)[16](https://peptidevox.com/#r16) It is not indicated in pregnancy or lactation. Notably, the osteosarcoma question is the only tumor concern here with a real mechanistic basis, and human data have not borne it out — there is no credible angiogenesis-driven cancer signal in the human literature.[4](https://peptidevox.com/#r4)

## What is the FDA and WADA status in 2026?

Teriparatide is an FDA-approved prescription drug — Forteo (Eli Lilly), approved November 2002 for osteoporosis at high fracture risk, with the boxed osteosarcoma warning and 2-year lifetime limit removed effective November 16, 2020.[4](https://peptidevox.com/#r4)[5](https://peptidevox.com/#r5) Brand exclusivity lapsed in 2019; a 505(b)(2) follow-on (PF708/Bonsity) was approved in October 2019, EU biosimilars (Qutavina, Livogiva, Sondelbay, Movymia) followed from 2020, and a substitutable generic teriparatide reached the US market around November 2023.[17](https://peptidevox.com/#r17)[18](https://peptidevox.com/#r18) As an FDA-approved commercial product it is normally dispensed as the manufactured pen rather than compounded, so no 503A Category-2 bulk-substance controversy comparable to the unapproved research peptides applies. It is not a DEA controlled substance.[15](https://peptidevox.com/#r15)

For athletes, teriparatide is not specifically named on the WADA Prohibited List and has no demonstrated performance-enhancing effect in healthy adults — its action is on bone remodeling, not muscle or endurance. As a peptide hormone, athletes should still verify current status on GlobalDRO by brand and ingredient and, if treating genuine osteoporosis, consider a Therapeutic Use Exemption, since strict-liability rules apply.[20](https://peptidevox.com/#r20)[21](https://peptidevox.com/#r21) Branded Forteo historically cost more than $5,000 per pen; biosimilars and generics price roughly 20–40%+ lower.[19](https://peptidevox.com/#r19)

**Bottom line.** Teriparatide is among the best-validated peptide drugs in this field — a genuine, FDA-approved bone-anabolic hormone with Grade A RCT evidence for reducing vertebral and nonvertebral fractures in high-risk osteoporosis, and proven superior to a standard antiresorptive on fracture endpoints. The honest caveats for a bone-healing audience: its proven benefit is fracture *prevention*, not acute fracture *healing*; for off-label fracture-healing use the evidence is Grade B at best and unproven for hard union rates; and it is a costly, refrigerated, daily self-injected prescription biologic, not a casually obtained research peptide. Verdict: proven and important within osteoporosis, promising-but-unproven for accelerating fracture healing, and not a performance agent.

---
Source: https://peptidevox.com/peptide-encyclopedia/teriparatide
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt